Advertisement

Interleukin-1 Production by Mononuclear Cells and Natural Killer Cell Activity in Children with Acute Lymphoblastic Leukemia

  • A. Chybicka
  • J. Boguslawska-Jaworska
  • W. Budzyński
  • Cz. Radzikowski
  • W. Jaworski
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Interleukin 1 (IL-1) plays a major role in the response to infection, in inflammation, and in every immunological challenge. Over the past 10 years a variety of additional activities, especially of purified IL-1 on various target cells in vitro, has been reported [1]. As shown by Shirakawa et al. [2], IL-1 enhances also natural killer (NK) cell cytotoxic effect and proliferation. Expression of IL-2 receptors on NK cell surface can be regulated by IL-1 [3]. [4] Although IL-1 acts directly on many immunocompetent cells its role in malignant diseases has not yet been extensively explored [5]. We have previously reported apparent deficiency of IL-1 production by mononuclear cells of children with acute lymphoblastic leukemia (ALL) during the whole period of cytostatic therapy [6].

Keywords

Natural Killer Acute Lymphoblastic Leukemia Natural Killer Cell Activity Natural Killer Activity Natural Killer Cell Number 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fibbe E, Schaafsma MR, Falkenburg FJ, Willmze R (1989) The biological activities of interleukin 1. Blut 59: 177CrossRefGoogle Scholar
  2. 2.
    Shirakawa F, Tanaka Y, Eto S, Suzuki H, Yodo Y, Yamashita U (1986) Effect of interleukin 1 on the expression of interleukin 2 receptor (TAC antigen) on human natural killer cells and natural killer-like cell line (YT cells). J Immunol 137: 551PubMedGoogle Scholar
  3. 3.
    Kataoka Y, Todo S, Morioka Y, Sugie K, Nakamura Y, Yodoi J, Imashuku S (1990) Impaired natural killer activity and expression of interleukin 2 receptor antigen in familial erythophagocytic lymphohistiocytosis. Cancer 65: 1937PubMedCrossRefGoogle Scholar
  4. 4.
    Peppoloni S, Bossu P, Boraschi D, Tagliabue A (1989) A short synthetic peptide fragment of human interleukin 113 increases both human and murine natural killer activity. Nat Immun Cell Growth Regul 8: 10–19PubMedGoogle Scholar
  5. 5.
    Herman JA, Kew MC, Rabson AR (1984) Defective interleukin-1 production by monocytes from patients with malignant diseases: interferon increasas IL-1 production. Cancer Immunol Immunother 16: 182–185PubMedCrossRefGoogle Scholar
  6. 6.
    Chybicka A, Boguslawska-Jaworska J (1990) Interleukin 1 production in childhood acute lymphoblastic leukemia during chemo-and radiotherapy according to BFM (BerlinFrankfurt-Munster) protocol. In: Büchner T et al. Acute leukemias II. Berlin Heidelberg New York 33: 72 (Hematology and blood transfusion)Google Scholar
  7. 7.
    Frydecka I (1985) Natural killer cell activity during the course of disease in patients with Hodgkin’s disease. Cancer 56: 2799PubMedCrossRefGoogle Scholar
  8. 8.
    Pross HF, Maroun JA (1984) The standardisation of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 68: 235PubMedCrossRefGoogle Scholar
  9. 9.
    Zimecki M, Wieczorek Z (1987) IL-1 decreases the level of thymocytes forming rosettes with autologous erythrocytes, a new method of determination of I1–1 activity. Arch Immunol Ther Exp (Warsz) 355: 371Google Scholar
  10. 10.
    Migliorati G, Cannarile L, D’Adamio L, Herberman RB, Riccardi C (1987) Interleukin 1 auguments the interleukin 2 dependent generation of natural killer cells from bone marrow precursor. Nat Immun Cell Growth Regul 6: 306PubMedGoogle Scholar
  11. 11.
    Pross HF, Baines M (1987) Alterations in natural killer cell activity in tumor-bearing hosts. In: Herberman RB, et al. (eds) Immune responses to metastases. CRC Press, Boca Raton, p 57Google Scholar
  12. 12.
    Lange A, Flad HD, Jack A, Ulmer AJ (1986) Effect of human recombinant interleukin 2 on natural killing of low density percoll fraction cells. Immunol Lett 12: 243–250PubMedCrossRefGoogle Scholar
  13. 13.
    Douer D, Shaked N, Ramot B (1987) Normal natural killer activity in Hodgkin’s disease patients in remission. Clin exp Immunol 69: 660–667PubMedGoogle Scholar
  14. 14.
    Mehta BA, Satam MN, Advani H, Nadkarin JJ (1989) In vitro modulation of natural killer cell activity in non-Hodgkin’s lymphoma patients after therapy. Cancer Immunol Immunother 28: 148–152PubMedCrossRefGoogle Scholar
  15. 15.
    Tanaka Y (1981) Natural killer NK activity in children with acute lymphoblastic leukemia. Hiroshima J Med Sci 30: 127PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. Chybicka
    • 1
  • J. Boguslawska-Jaworska
    • 1
  • W. Budzyński
    • 2
  • Cz. Radzikowski
    • 2
  • W. Jaworski
    • 3
  1. 1.Department of Hematology and OncologyMedical AcademyWroclawPoland
  2. 2.Department of Tumor ImmunologyInstitute of Immunology and Experimental Therapy Polish Academy of ScienceWroclawPoland
  3. 3.Department of Children SurgeryMedical AcademyWroclawPoland

Personalised recommendations